Clinically relevant materials & applications inspired by food technologies

Xi Cui,a,b,c Kuan Rei Ng,c Kong Fei Chai,c and Wei Ning Chenc,d*

Interdisciplinary Graduate School, Nanyang Technological University, 50 Nanyang Avenue, 639798, Singapore
Advanced Environmental Biotechnology Centre, Nanyang Environment & Water Research Institute, Nanyang Technological University, 1 CleanTech Loop, CleanTech One, No. 06-08, 637141, Singapore
Food Science and Technology Programme, Nanyang Technological University, 62 Nanyang Drive, 637459, Singapore
School of Chemical and Biomedical Engineering, Nanyang Technological University, 62 Nanyang Drive, 637459, Singapore

Summary

Food science and technology have a fundamental and considerable overlap with medicine, and many clinically important applications were borne out of translational food science research. Globally, the food industry - through various food processing technologies - generates huge quantities of agro-waste and food processing byproducts that retain a significant biochemical potential for upcycling into important medical applications. This review explores some distinct clinical applications that are fabricable from food-based biopolymers and substances, often originating from food manufacturing side streams. These include antibacterial wound dressings and tissue scaffolding from the biopolymers cellulose and chitosan and antimicrobial food phytochemicals for combating antibiotic-resistant nosocomial infections. Furthermore, fermentation is discussed as the epitome of a translational food technology that unlocks further therapeutic value from recalcitrant food-based substrates and enables sustainable large-scale production of high-value pharmaceuticals, including novel fermented food-derived bioactive peptides (BPs).

Copyright © 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Keywords: Food technologies; Clinical applications; Biocompatible materials; Natural antimicrobials; Fermentation

Introduction

The term “food science & technology” refers to a huge multidisciplinary umbrella spanning the basic sciences and engineering fields and their interfaces with human food and all aspects thereof. As food sustains all forms of life, fundamental overlap exists between food science and medicine. In addition to the universally acknowledged concept of “food as medicine” (termed “yaoshitongyuan” in traditional Chinese medicine), there are many other diverse facets of food science and technology that are also highly translatable to clinical applications. “Clinical application” refers to research that is directly applied to patient medical testing and/or treatments. The global food industry juggernaut – valued at USD 11 trillion in 2019 and growing rapidly – generates both agro-waste (from crop agriculture) and food processing side-streams (from food manufacturing) at enormous scale daily.1,2 The in principle high biocompatibility of food-derived substances and matrices, combined with their superior homogeneity over public food waste, makes these food production side-streams highly convenient and reliable bioresources - still ripe with biochemical riches and strong potential for valorisation and upcycling into impactful biomedical and clinical applications. Notable examples of such food side streams include sugarcane bagasse, coffee grounds, soybean okara and brewers’ spent grain. Unfortunately, valorisation and upcycling of these food side streams are not yet common practice, with most food-related businesses simply opting for pure disposal.

In this review, we expand on various distinct impactful clinical applications derivable from or inspired by food-based bioreources and food science & technology approaches (Figure 1). Of particular interest are solutions borne out of food waste valorisation approaches towards the twin goals of reducing global food waste and the global carbon footprint. Fermentation is the quintessential translational food technology that connects these discussed facets by unlocking further value from recalcitrant food waste substrates and enabling sustainable large-scale production of high-value naturally scarce pharmaceuticals via sophisticated biotechnological schemes (Tables 1–3).

Food processing side streams refer to byproducts originating from any stage of a food manufacturing process via various food technologies. These side streams are generated in huge volumes daily by the global food
**Figure 1.** Summary of biomedical applications that can be derived from food technologies.

| Biomaterials                      | Clinical Application                                                                 | Refs. |
|-----------------------------------|--------------------------------------------------------------------------------------|-------|
| Cellulose                         | Wound dressing (hydrogel), antimicrobial, anti-freezing, non-drying properties       | 4     |
|                                   | Wound dressing (film), exudate absorption, controlled drug release                   | 5     |
|                                   | Tissue engineering, skin and bone                                                   | 16    |
|                                   | Sensor for personal health care monitoring (paper)                                   | 20    |
|                                   | Biosensor (hydrogel)                                                                | 30    |
|                                   | Tissue engineering, bone                                                            | 15    |
|                                   | Drug delivery                                                                        | 23    |
| Cellulose nanofibril              | Wound dressing, Antimicrobial property and mode of action                            | 6     |
| Nanocrystalline cellulose         | Wound dressing, Antimicrobial property                                               | 7     |
| Chitosan                          | Wound dressing, Antimicrobial property                                               | 8     |
|                                   | Wound dressing, Antimicrobial property                                               | 9     |
|                                   | Wound dressing (hydrogel), Haemostatic                                              | 12    |
|                                   | Surgical suture                                                                      | 13    |
|                                   | Surgical suture, improved colonic anastomosis                                        | 14    |
|                                   | Tissue engineering (hydrogel), kidney-specific                                       | 17    |
|                                   | Drug delivery, kidney-specific                                                       | 25    |
|                                   | Drug delivery, antimicrobial, rechargeable                                           | 26    |
|                                   | Hypocholesterolaemic                                                                 | 31    |
|                                   | Haemostasis                                                                          | 10    |
|                                   | Antimicrobial against multi-drug resistant bacteria                                   | 32    |
|                                   | Tissue engineering (hydrogel), bone                                                  | 18    |
| β-chitosan                        | Drug delivery, targeted                                                              | 27    |
| Alginate                          | Tissue engineering (hydrogel)                                                        | 19    |
|                                   | Tissue engineering for vascular medicine                                             | 20    |
|                                   | Tissue engineering, bone                                                             | 21    |
| Oxidized alginate                 | Drug delivery, transdermal                                                           | 26    |
| Collagen                          | Drug delivery (hydrogel), controlled release                                         | 24    |
| Fibrin                            |                                                                                      |       |
| Gelatine                          |                                                                                      |       |
| Nano-carboxymethyl cellulose-alginate-chitosan                                    |       |

**Table 1:** Food-derived biopolymers and their clinical applications, sorted by biopolymer type.
### Table 2: Plant food-derived antimicrobials, their specific activity and potential clinical applications.

| Food Source                     | Compound        | Clinical Application | Antimicrobial Activity Against                      | Refs. |
|---------------------------------|-----------------|----------------------|-----------------------------------------------------|-------|
| Ashitaba (Angelica keiskei)     | Isobavachalcone | Antibiotic lead       | MRSA, VRE                                           | 58    |
| Mangosteen (Garcinia mangostana) | a-mangostin     | Antibiotic lead       |                                                     |       |
| Tea (Camellia sinensis)         | Complex Extract | Adjuvant to Naldixic acid | MDR Salmonella typhi                               | 42    |
| English walnut (Juglans regia)  | Complex Extract | Adjuvant to Oxacillin | MRSA                                               |       |
| Coffee (Coffea spp.)            | Caffeine        | Adjuvant to Gentamicin| Staphylococcus aureus (clinical isolate)            | 47    |
| Various food crops & herbs      | Verbascoside    | Adjuvant to Gentamicin| S. aureus (clinical isolate), MRSA, Escherichia coli (clinical isolate) | 47    |
| Lemon verbena (Lapis citriodora)| Complex Extract | Adjuvant to Gentamicin| S. aureus (clinical isolate)                       |       |
| Pomegranate (Punica granatum)   | Complex Extract | Adjuvant to Novobiocin| Acinetobacter baumannii                             | 59    |
| Lemon grass (Cymbopogon citratus)| Essential oil   | Adjuvant to Chloramphenicol| Enterobacter aerogenes EA27, E. coli AG102         | 49    |
| Chlorophyll-containing foods    | Phytol          | Surface disinfectant  | E. coli, Candida albicans, Aspergillus niger       | 52    |
| Oregano (Origanum vulgare), cinnamon (Cinnamonum sp.), clove (Syzygium aromaticum) | Essential oil mixture | Surface disinfectant | E. coli, mesophilic aerobic bacteria, yeasts & moulds | 53    |
| Marjoram (Origanum majorana)    | Essential oil   | Surface disinfectant  | E. coli, Listeria monocytogenes                    | 54    |
| Thyme (Thymus vulgaris)         | Essential oil   | Surface disinfectant  | E. coli, Listeria monocytogenes                    |       |

### Table 3 (Continued)

| Source            | Product       | Bioactive peptides                                                                 | Bioactivities                                                                 | Refs. |
|-------------------|---------------|------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------|
| Cow’s milk        | Cultured milk | P1: QYLSRYSYPSYG/6P2: KYPIQYVLS/3: INQFLPYPPYAKPA/4: DKTEIPTINTIASEGPT/5: AVRSPAQILQWQ/6: VIESPPEINTVQ/7: NTVPAKSCQAOPTt/8: NVPGEIVESL/9: VYPFPGIPTP/10: HKEMPFPKYPVPEFTEQ/11: SQSKWLPVPQKAVPYPQ/12: SWMHQHPQHPPLPPT/13: VVPPFLOPE/14: EDELQDKIHPF/15: FPKYPVEF/16: APSFSDDINPGSENSE/17: KHOQLPQDEVLENEL/18: PIPEVFGKERE/19: QGPIVWNPWDDQVR/20: ALPQYKYTVYQHQK/21: IQPKTKVYQVYLY | Antibacterial (P4, P6 and P20-P22), immuno-modulating (P8 and P17) and ACE-I (P9) | 70    |
| Source                     | Product               | Bioactive peptides                                                                 | Bioactivities                                                                 | Refs. |
|----------------------------|-----------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|--------|
| Prato cheese               |                       | P22: FLKKISQYQYKF<br>P23: EKQGTQTPKELVPSH<br>P1: α-CN(f1-9) (m/z 1141)<br>P2: β-CN(f194-209) (m/z 1718)<br>P3: β-CN(f193-206) (m/z 1556) | Antihypertensive (P1 and P3) and ACE-I (P1 and P2)                          | 71     |
| Fermented milk             |                       | P1: VPP<br>P2: IPP<br>P3: LKP<br>P4: ALPM<br>P5: PGHID<br>P6: VAGTWY<br>P7: DN<br>P8: SPI | ACE-I                                                 | 66     |
| Yoghurt                    |                       | GABA<br>P1: YQEPVLGPRGPRPVAL<br>P2: SPQNPPLQTPVWPFF | Antihypertensive, antidiabetic and antiproliferative<br>Antioxidant and antiproliferative | 65     |
| Pork                       | Pork protein extract  | P1: MDLR<br>P2: PYL<br>P3: FDLR<br>P4: EAPYLR<br>P5: EAAPYL<br>P6: AAPYLR<br>P7: KALLS<br>P8: VLAR<br>P9: LPLK<br>P10: AKLPA<br>P11: VNGFER<br>P12: KLP<br>P13: YGERAL<br>P14: WFK<br>P15: APAKFR<br>P16: KPSL<br>P17: THLDT<br>P18: FLSNH<br>P19: WLG<br>P20: AKLPA<br>P21: KIAP<br>P22: KPSPL<br>P23: LLVH<br>P24: KPSPLL<br>P25: VLLFH | Antioxidant                                      | 73     |
| Ruditapes philippinarum    | Clam                  | P1: VISVEDGVTH<br>P2: LDSSDGVTH<br>P3: WVGDAVGK<br>P4: FAGDDAPRA | ACE-I                                                                       | 73     |
| Soybean                    | Natto                 | P1: KFKNFYGR<br>P2: FFPRPPHPHQK<br>P3: GQOSSQPODRHQQK<br>P4: QFFDOQSPQ<br>P5: EROQFPFPHPHQK<br>P6: GEIRPRPRPQPHPE<br>P7: EQRPRPPRPQPR | Angiogenic (P1-P5 and P7) and lipopolysaccharide-neutralizing (P1-P7) activities | 74     |
| Chicken feather            | -                     | P1: LPGPILSSFPQ | Antioxidant                                                            | 75     |

Table 3: Selected peptides with bioactivities obtained from various food sources via microbial fermentation.
industry. Valuable raw materials (green) are extracted from these side streams and then converted into impactful clinical applications (blue). Fermentation (red) is a pivotal translational food technology for the value-added transformation of these recalcitrant materials into such applications.

**Biocompatible food-based biopolymers derived via food processing technology for clinical biomaterial applications**

In medical and clinical sciences parlance, “biomaterial” refers to any polymer or substance that has been engineered to interact with biological tissues or systems for therapeutic or diagnostic purposes, while “biocompatibility” refers to said material’s propensity to elicit undesirable immunological or toxic responses from the patient. Clinical applications necessitate biomaterials to be biocompatible as well as certified medical grade to minimize immune rejection and infection risks, respectively - particularly important in invasive surgical implementation cases. For clinical biomaterial applications, natural biopolymers have some inherent advantages over synthetic petroleum-based or inorganic biomaterials (glass, ceramic, metals), such as overall higher biocompatibility. Food in all forms consists of some combination of all of the different existing biopolymers (carbohydrates, proteins and polynucleotides) and is by definition highly biocompatible and therefore a robust fit for almost all clinical biomaterial applications. The polysaccharides cellulose and chitosan tend to dominate, followed by fibrous protein-derived polypeptides such as collagen and gelatine. Cellulose is the most abundant biopolymer in nature, consisting of a linear chain of \( \beta -1,4 \)-linked D-glucose units. The omnipresence of cellulose in food makes it both highly viable and economical as a substitute for petrochemical-derived plastic polymers, particularly in wound care applications such as dressings and sutures. Chitin, the second most abundant biopolymer on Earth, is another similarly linear polysaccharide built from \( \beta -1,4 \)-linked N-acetylglucosamine units and a principal component of the exoskeletons and exotoxins of insects, fungi, invertebrates and fish. Chitin can be further deacetylated by chemical or enzymatic means to yield chitosan, the true biopolymer of interest, especially for wound care. Unique chemical and biological properties are liberated by the deacetylation of the chitin backbone monomers, which vastly improves aqueous solubility and antimicrobial activity as a result of the exposed amino moieties on the glucosamine monomer subunits. Plant crop and seafood processing side streams are hugely underutilized and highly sustainable sources of cellulose and chitosan, respectively, which are usually extracted via energetic hydrolysis-based approaches to be fabricated into wound care, tissue scaffolding or drug delivery applications, expanded on below.

**Wound dressings**

Wound dressings are widely used in clinical settings - especially postsurgery - to avoid secondary injury, minimize infection risk and accelerate wound healing and recovery. Presently, synthetic polymers are the market default in wound care due to cost and abundance. The primary weaknesses of synthetic polymer-based wound dressings – low biocompatibility and biodegradability – nevertheless remain. In terms of biocompatible substitutes, hogs’ skin or human skin grafts were discovered very early to be effective at protecting deeper skin tissue layers from further physical damage and infection while also retaining strong water permeability. However, due to their high cost and perishability, such natural skin grafts were quickly determined to be clinically impractical. Cellulose is a strong substitute candidate due to its superior biocompatibility, biodegradability, sustainability and low solubility in common organic solvents. Cellulose derived from valorisation of Durian husk was successfully used to fabricate hydrogel wound dressings with both anti-freezing and antimicrobial properties (Figure 2).\(^4\) Cellulose has also been combined with chitosan and alginate – all food-grade biopolymers - to form a highly biocompatible biomaterial composite applied as a direct wound dressing that was found to be capable of both wound exudate absorption and controlled release of topical medications.\(^5\) Chitosan, with its inherent antimicrobial property, is theoretically superior to cellulose for wound care applications.\(^6,7\) Chitosan has been combined with polyvinyl alcohol and copper to successfully demonstrate antimicrobial activity against both gram-positive and gram-negative bacteria.\(^8\) In another work, chitosan was incorporated with clove and melaleuca essential oils to form an antimicrobial film for wound dressing.\(^9\) Haemostatic potential – a particularly desirable quality for wound dressings - of chitosan was also observed in studies\(^10,11\) with a chitosan/cyclodextrin hybrid hydrogel reportedly exhibiting a good haemostatic effect by decreasing the blood loss and shortening haemostasis times.\(^12\)

**Surgical sutures**

Another important aspect of wound care in clinical settings is that sutures are typically used in invasive surgery to seal deeper surgical incision wounds to facilitate postoperative healing and recovery of the patient. Similar to wound dressings, while modern sutures are mostly synthetic and petroleum-based, biocompatibility, biodegradability and antimicrobial effects remain desirable properties for surgical sutures, particularly since sutures are commonly not physically removed but left to safely biodegrade within the patient. Cellulose filaments accordingly show promise as sutures and artificial vasculature in microsurgery procedures, wherein oxidized regenerated cellulose can prevent haemorrhage, a serious medical complication. Additionally,
chitosan’s similarly strong potential here was demonstrated via enhanced antimicrobial, mechanical, and frictional properties when it was coated on the surface of synthetic nylon sutures. In another work, chitosan-coated surgical sutures were applied in colonic anastomosis, showing improved adhesion and reinforcement both in vitro and in vivo.

**Tissue engineering**

Tissue engineering is a highly interdisciplinary clinical subfield that involves tissue or whole organ regeneration/replacement from specific cellular growth — often on tissue scaffolds — as a therapeutic approach. Biocompatibility and biodegradability are once again important prerequisites. Cellulose expectedly shows strong potential as a tissue scaffolding material in tissue transplantation as well as bone and skin tissue engineering. Thermosensitive chitosan hydrogel was also used as an injectable scaffold to deliver mesenchymal stem cells to targeted sites for the treatment of acute kidney injury, resulting in the amelioration of renal function and tubular cell proliferation. Alginate, another less common food polysaccharide polymer derived from edible brown seaweed, has unique clinical potential owing to its anionic and gelling properties when combined with divalent cations, e.g., Ca$^{2+}$. and has seen applications in tissue engineering as well. For nonpolysaccharide-based biopolymers, collagen, an extracellular matrix protein and the most abundant protein in mammals present as connective tissue in tendon, ligament, and skin, is an obvious candidate as a scaffolding biomaterial, while fibrin, another protein derived from meat wastes, also seems to be useful. In one highly innovative study, stale bread — typically an undefined solid matrix of carbohydrates and proteins — was utilized as raw material for bioactive scaffolds.

**Drug delivery**

Drug delivery involves the transport of pharmaceutical compounds to target tissue(s) and/or organs, usually involving drug carriers that control their rate of release and absorption into the target tissue to achieve a desired therapeutic effect at the appropriate dose. Food biopolymers are all naturally excellent fits as drug carriers and have been trialed extensively via myriad formulations. Nanocrystalline cellulose and modified carboxymethyl cellulose have been used in drug delivery systems, either on their own or in composites with other biopolymers. Low molecular-weight chitosan can be used to fabricate tissue-directed drug delivery nanocomplexes for renal fibrosis treatment, and its unique renal tissue-specific property is attributable to the presence of primary amines on the backbone glucosamine units. Methacrylic acid-modified polyurethane was also combined with antimicrobial chitosan to ensure aseptic drug delivery. Alginate nanoparticles and gelatine have seen similar drug delivery applications.

**Other clinical applications of food-based biopolymers**

Cellulose has shown strong potential as a biosensor implant material. NiSe$_2$-modified cellulose was used to fabricate a biosensor cum personal health care monitor, and okara-derived cellulose was fabricated into hydrogels for human movement detection as a biosensor. A hypocholesterolaemic effect of chitosan in humans was also observed before lowering the serum low-density lipoprotein (LDL) cholesterol matrix of carbohydrates and proteins — was utilized as raw material for bioactive scaffolds.
Natural food antimicrobials to counter antibiotic resistance and nosocomial infections

Antibiotic resistance in pathogens has become a major global public health problem. Continual misuse of antibiotics in humans and livestock has created multiple multidrug resistant (MDR) pathogenic strains, against which modern medicine is running out of treatment options. MDR-associated nosocomial or hospital-acquired infections are of particular concern due to significantly increased patient mortality risk. The strains of high concern are carbapenem-resistant *Acinetobacter baumannii*, *Pseudomonas aeruginosa* and *Enterobacteriaceae*. Antibiotic resistance in pathogens can arise through numerous mutations via many different possible microbial mechanisms: biofilm formation, altered enzyme or ligand binding site affinities, efflux pumps, deactivate enzymes, e.g., beta-lactamases, etc. Natural food antimicrobials – the majority of which are plant-derived antimicrobial phytochemicals – represent potent novel leads against MDR pathogens via the following applications: antibiotic therapy, surface disinfectants or sanitizers and enhancement of personal protective equipment (PPE) in clinical settings. Similar to food-based biopolymers, food production side streams represent rich and readily available biosources to tap for antimicrobial phytochemicals of interest.

Antimicrobial phytochemicals for antibiotic therapy

Plant natural compounds or phytochemicals remain a precious yet largely untapped resource in the war against MDR pathogens, with antibiotics mostly of microbial or synthetic origin, rather than botanical origin, employed today. Plant secondary metabolites are divided into classes such as terpenoids, alkaloids, organosulfur compounds and phenolics and are often relatively small molecules (lower Mr range < 500) in comparison to other classes of active lead compounds, e.g., peptides and biologics. For the screening of plant materials for antibiotic drug discovery, there remains significant room to explore using ethnopharmacological, computational and sometimes serendipitous approaches. Phytochemicals may be utilized in antimicrobial applications as either highly purified lead compounds or botanical extracts, which are complex mixtures of plant essential oils (EOs). The antimicrobial potential of myriad dietary phytochemicals has been widely reported in the literature based on different mechanisms depending on molecular structure: efflux pump inhibitory activity, protein alkylation, different enzyme inhibition and bacterial membrane disruption. It has also been proposed and observed that synergism between phytochemical components of a complex botanical extract may result in improved antimicrobial effects over single purified phytochemicals.

Antimicrobial phytochemicals as disinfectants, sanitizers and enhanced personal protective equipment (PPEs)

The strong translational potential of natural food antimicrobials for clinical applications is not limited to only...
antibiotic therapies but also to surface disinfectants, sanitizers or enhanced personal protective equipment (PPE) via incorporation of antimicrobials into their fabric or material — of particular importance in the present COVID-19 pandemic (Figure 3). Relevant examples are as follows: Phytol derived from *Leptadenia pyrotecnicais* was trialled and showed promising, dose-dependent disinfectant properties against bacteria, yeast and mould.\(^{52}\) In another work, a combined oregano-cinnamon-clove essential oil formulation showed a strong reduction in total mesophilic aerobic bacteria and mould-yeast counts on various surfaces as well as air.\(^{53}\) Another study showed thyme and marjoram EO-based disinfectants to be effective at eliminating *E. coli* and *Listeria monocytogenes* biofilms on polypropylene surfaces, and their effects were equivalent or even superior to industrial sanitizers based on per-acetic acid or sodium hypochlorite.\(^{54}\)

Plant antimicrobials are typically produced via large-scale extractions (maceration, hydrodistillation, Soxhlet, etc.) of medicinal or food crop biomass — either foraged or cultivated - which creates considerable detrimental environmental impact via deforestation, significant waste generation and a carbon footprint. Agricultural crop byproducts and food processing side streams are typically phytochemical rich and are highly economical yet environmentally friendly alternative sources of such compounds.\(^{55}\) These waste streams may be more ideal sources because they typically consist of fibrous, human-indigestible and inedible plant matter, e.g., seed husks, spent grain, and other lignocellulosic biomass, which conversely accumulate higher amounts of active phytochemicals per unit dry mass. In addition to food extraction technologies, fermentation is another key technology increasingly used to sustainably unlock and extract these valuable phytochemicals from such recalcitrant waste biomass. There is a fast-growing body of literature on the antimicrobial activities of food processing and agricultural byproducts, including their upcycling into potential food applications.\(^{56,57}\) An antimicrobial reusable face mask was recently commercialized in Singapore, wherein the active antimicrobial component in the mask fabric was derived from industrial nut processing waste (https://www.straitstimes.com/singapore/ntu-scientists-use-antimicrobial-extract-from-seeds-in-reusable-masks). This represents a tangible result of translational research between food science and medicine that is also highly environmentally sustainable and a keynote example in this review.

**Figure 3.** Antimicrobial phytochemicals for combating multidrug-resistant pathogens in clinical settings. Antimicrobial phytochemicals are derived from natural plant sources or, alternatively, food processing side streams. Via extraction methods that may involve fermentation, antimicrobial botanical extracts or purified lead compounds derived therefrom are then used for antibiotic therapy, disinfectants and sanitizers and infused into PPEs for enhanced protection.

**Fermentation as a pivotal food technology for unlocking pharmaceuticals and good health**

In food science and biotechnology, fermentation refers to the chemical transformation of organic material from and for food purposes via utilization of microbial metabolism. Fermentation typically results in radically altered final products that are nevertheless desirable due to certain compositional and organoleptic profile changes. Despite being a millennia-old practice and one of the oldest food technologies in existence, fermentation is far from being solved or perfected. Countless types exist – from ancient undiscovered artisan recipes brewed in remote regions to highly sophisticated and precise biotechnological schemes. The breadth and depth of
Fermentation science & technology have expanded immeasurably in the past century and continue apace. Historically, some key breakthroughs in fermentation were closely tied to medicine, in the case of penicillin and insulin, which both represent key milestones of “red” or medical biotechnology. The pasteurization process still stands today as the monumental translational research breakthrough between food science and medicine. In the future, the continuing development and maturation of synthetic biology and metabolic engineering subfields further enable precision fermentation approaches for sustainable high-volume production of natural bioactives and pharmaceuticals. Herein, we discuss food fermentation-derived bioactive peptides as prospective novel pharmaceuticals that are underexplored and distinct from established, well-characterized biologics such as insulin, polypeptide drugs and vaccines.

**Fermentation of biologically active peptides with diverse health benefits**

Bioactive peptides (BPs) are specific protein fragments that are initially inactive within the sequence of the parent protein but are then liberated via microbial enzymatic and proteolytic activities during fermentation processes. BPs have shown various physiological functions, such as antihypertensive, antioxidant, antimicrobial, anticancer, anti-inflammatory, opiate-like, hypolipidaemic and hypocholesterolaemic, antithrombotic and mineral binding activities. These potent physiological effects, allied with high target biospecificities, low bioaccumulation potential and allergenicity risks, make BPs highly attractive and promising novel pharmaceutical candidates with a wide spectrum of potential clinical applications. To date, BPs from food-based fermentations are still a largely unexplored arena. The most common BPs reported in the literature are angiotensin-converting enzyme (ACE) inhibitory peptides. ACE inhibitory peptides are of particular interest as COVID-19 drug candidates, in light of the recent ongoing pandemic. The bioactivities exerted by BPs depend on their structural properties, amino acid composition and sequence - usually with 2-20 amino acid residues and of low molecular weight (<6 kDa) - and in particular identity of N- and C-terminal residues.

Fermentation has been used to hydrolyse food proteins to liberate BPs from their parent proteins via the action of proteases synthesized by fermenting organisms. Yeasts, fungi and lactic acid bacteria (LAB) are typical fermentation starter cultures, with LAB preferring over others due to their generally recognized as safe (GRAS) status. Both solid-state and submerged fermentations have been employed on many different food sources to obtain BPs, including milk and dairy products, meat, cereals, pseudocereals and legumes, fish and shellfish, microalgae, and wastes from agri-food processing. Gamma aminobutyric acid (GABA) is a nonprotein amino acid that can be synthesized via microbial fermentation: GABA can decrease blood pressure, reduce stress, prevent diabetes and inhibit cancer cell proliferation. The presence of high levels of GABA in yogurt contributes to its popularity as a functional dairy product that can be conveniently consumed with regularity. A recent study showed that the GABA content in yogurt could be further enhanced via the addition of simple sugars and commercial prebiotics without the need for pyridoxal 5'-phosphate (PLP) cofactor, a critical coenzyme for most LAB strains that is present at low levels for GABA production through $\alpha$-decarboxylation of glutamate via glutamate decarboxylase, hinting at an alternative and more feasible long-term therapeutic regime or approach for chronic hypertensive patients. The commercially available and widely known fermented milk-based beverages Calpis and Evolus both claim to contain antihypertensive triptides Val-Pro-Pro and Ile-Pro-Pro and could thus fit the same purpose.

Aside from exerting physiological functions instantaneously, many peptides have also demonstrated prodrug properties via gut release by enzymatic activity on ingested food containing protein precursors. The multifunctional $\beta$-casein-derived peptides Tyr-Gln-Glu-Pro-Val-Leu-Gly-Pro-Val-Arg-Gly-Pro-Phe-Pro-Ile-Ile-Val and Ser-Leu-Pro-Gln-Asn-Ile-Pro-Pro-Leu-Thr-Gln-Thr-Pro-Val-Val-Pro-Pro-Phe reported in a fermented milk study demonstrated that further in vitro gastrointestinal digestion increased their antioxidant and antiproliferative activities, while a whey protein hydrolysate produced by Davisco Foods International, USA, contains glycomacropeptides that purportedly possess anticarcinogenic, antimicrobial and antithrombotic activities. By markedly improving overall gut health, these BPs have the potential to be administered as prebiotic therapy for patients with irritable bowel syndrome, which affects approximately 1 in 10 patients in the United States.

Fermentation is a novel approach for the production of a myriad of health-beneficial BPs, requiring a lower cost compared to enzymatic hydrolysis. Additionally, BPs obtained from microbial fermentation can be purified without further hydrolysis. It is envisaged that once the structure and sequence of a specific BP have been elucidated, precision fermentation could be employed - via engineered microbial platform approaches - to produce the target BP more efficiently and sustainably. The combination of rapidly maturing next-generation sequencing, high-throughput screening and multi-omics approaches in tandem with synthetic biology and metabolic engineering tools will enable ever more precise strain selection, design and optimization of high-productivity microbial cell factories for the production of BPs from various protein sources - either animal or plant origin - or even from low- to zero-value food waste substrates via precision fermentation.
Review

Outstanding Questions
Despite the sizeable body of work accomplished in medicine-directed translational food science research, significant challenges and obstacles remain to be overcome. The useful natural biopolymers cellulose and chitosan are locked behind highly recalcitrant waste biomass (lignocellulosic and chitinous, respectively), which typically require harsh physical and/or biochemical treatment approaches, and extraction from these waste bioresources has significant room for improvement in terms of efficiency, purity and process sustainability. Fermentation has the potential to alleviate these problems but remains largely untested. Despite their many advantages, pure cellulose and chitosan still possess some inherent weaknesses, e.g., mechanical strength, water solubility, and shelf life, that render them not an immediate fit for many applications, which therefore necessitates further innovative engineering – such avenues include composite formulation and polymer functionalization. For natural antimicrobials against antibiotic resistance, phytochemicals as adjuvants in antibiotic therapy have demonstrably worked; further research remains in terms of optimizing drug formulations and dosages for clinical application. The current library of identified and characterised plant natural products is vast, but the unidentified space that remains may be at least an order of magnitude larger. Ultimately, upscaling the production of all of these food-derived bioactive will address the key bottleneck: these phytochemicals or combinations thereof are produced naturally in only minute quantities, and despite rapid progress in the related subfields, precision fermentation via synthetic biology and metabolic engineering approaches remain some way from widespread commercial implementation, with money (capex costs), time (custom process design) and public perception (“naturalness”) being major stumbling blocks. Continual research efforts into fermentation science doubtless remain necessary to further optimize and streamline the design and implementation of precision fermentation approaches unique to each separate product.

Conclusion
Myriad clinical applications and solutions have been derived from the food science and technology arenas. As anedient yet inevitable consequence of agricultural and food processing technologies and manufacturing, industrial food side streams present obvious opportunities, as valuable bioresources are still rich in cellulose, chitin/chitosan, phytochemicals, (poly)peptides and lipids. Via interdisciplinary approaches and innovative methods borne out of translational food science research, such valuable bioresources could be readily transformed into biocompatible clinical biomaterials, antimicrobials, bioactive peptides and other valuable pharmaceuticals. Fermentation is key to unlocking the vast biochemical and clinical potential of recalcitrant food waste streams. The ability of fermentative microorganisms to catalyse the biotransformation of inedible and discarded nutritious, medicinal and even delicious microorganisms underlines fermentation’s tremendous value-add plus potential as a vital pillar of food technology to solve simultaneously the grand challenges faced by humanity today: reducing global food waste, averting climate change and improving public health.

Search strategy and selection criteria
All references in this review were identified by Google Scholar and PubMed engine searches using the following search terms or combinations and variations thereof: “agro waste”; “food waste isvalorisation”; “Natural biopolymers in medicine”; “Cellulose for medical applications”; “Chitosan for medical applications”; “Antimicrobial phytochemicals”; “antibiotic resistance”; “nosocomial infections”; “food fermentation”; “bioactive peptides”. All references fell within the timeframe 1965-2021, but the vast majority of cited works were from the past 10 years.

Contributors
All authors conceived the original draft and edited the final manuscript. All authors read and approved the final version of the manuscript.

Declaration of Competing Interest
The authors declare no competing interests.

Acknowledgements
The authors declare that this work was supported by a FoodTech@NTU Grant from Nanyang Technological University. FoodTech@NTU did not play any role in the study design, data collection, data analysis, interpretation, or writing of this manuscript.

References
1. Kamble DB, Rani S. Bioactive components, in vitro digestibility, microstructure and application of soybean residue (okara): a review. Legume Sci 2020;4(1):e12.
2. Vermi M, Pontonio E, Krena A, Jacob S, Pinto D, Rinaldi F, et al. Bioprocessing of brewers’ spent grain enhances its antioxidant activity: characterization of phenolic compounds and bioactive peptides. Front Microbiol 2020;11:831.
3. Bromberg BE, Song IC, Mohn MP. The use of pig skin as a temporary biological dressing. Plast Reconstr Surg 1965;36(1):30–50.
4. Cui X, Lee J, Ng KR, Chen WN. Food waste Durian rind-derived cellulose organogelators: toward anti-freezing and antimicrobial wound dressing. ACS Sustain Chem Eng 2021;9(1):1304–12.
5. Chang WS, Chen HH. Physical properties of bacterial cellulose composites for wound dressings. Food Hydrocolloids 2016;53:75–83.
6. Matica MA, Aachmann FL, Tøndervik A, Sletta H, Ostafe V. Chitosan as a wound dressing starting material: Antimicrobial properties and mode of action. Int J Mol Sci 2019;20(23):5889.
customized noninvasive personal healthcare monitoring. ACS Appl Electron Mater 2021;3(4):538–68.

20 Cui X, Lee JJ, Shen WN. Eco-friendly and biodegradable cellulose hydrogels produced from low cost okara: towards non-toxic flexible electronics. Sci Rep 2019;9(1):1–9.

21 Lijzjohann D, Marisova M, Woller K, Willeinck W, Bötticher N, Cooen M, et al. Influence of chitosan treatment on surrogate serum markers of cholesterol metabolism in obese subjects. Nutrients 2018;10(1):372.

22 Park SC, Nam JP, Kim JH, Kim YM, Nah JW, Jang MK. Antimicrobial action of water-soluble chitosan against clinical multi-drug resistant bacteria. Int J Mol Sci 2015;16(6):9795–8007.

23 Kouleit D, Song A, Ellingsoe B, Abdul-Aziz MH, Harris P, Gavey E, et al. Infections by multidrug-resistant Gram-negative Bacteria: what’s new in our arsenal and what’s in the pipeline? Int J Antimicrob Agents 2019;53(3):211–24.

24 Loyola S, Gutierrez I, Avendaño E, Severino N, Tamariz J. Multidrug-resistant bacteria isolated from cell phones in five intensive care units: exploratory dispersion analysis. Germs 2018;8(2):85–91.

25 Mulani MS, Kamble EE, Kumkar SN, Taware MS, Pardesi KR. Emerging strategies to combat ESRAPE pathogens in the era of antimicrobial resistance: a review. Front Microbiol 2019;10:519.

26 Willyard C. The drug-resistant bacteria that pose the greatest health threats. Nat News 2017;543(7643):15.

27 Shin J, Prabhakaran V, Kim KS. The multi-faceted potential of plant-derived metabolites as antimicrobial agents against multidrug-resistant pathogens. Microb Pathog 2018;116:209–14.

28 Stewart PS, William Costerton J. Antibiotic resistance of bacteria in biofilms. Lancet N Am Ed 2001;358(9269):335–8.

29 Díaz-Núñez JL, García-Contreras R, Castilla-Luizaro J. The new anti-bacterial properties of the plants: Quo vadis studies of anti-virulence phytochemicals? Front Microbiol 2021;12:1054.

30 Alsheikh HMA, Sultan I, Kumar V, Rather IA, Al-Sheikh H, Taseem IA, et al. Plant-based phytochemicals as possible alternative to antibiotics in combating bacterial drug resistance. Antibiotics 2020;9(8):480.

31 Trifan A, Luca SV, Greige-Gerhes H, Miron A, Gille E, Aprotosoaie AC. Recent advances in tackling microbial multidrug resistance with essential oils: combinatorial and nano-based strategies. Crit Rev Microbiol 2020;46(3):338–57.

32 Farooqui A, Khan A, Borghetto I, Kazmi SU, Rubino S, Paglietti B. Synergistic antimicrobial activity of camellia sinensis and juglans regia against multidrug-resistant bacteria. PLoS One 2015;10(2):39451.

33 Khamehni B, Iranzehayyeh M, Souheili V, Farzly Bazzaz BS. Review on plant antimicrobials: a microscopic viewpoint. Antimicrob Resist Infect Control 2019;8(1):128.

34 Ayaz M, Ullah F, Sadq A, Ullah F, Ovais M, Ahmed J, et al. Synergistic interactions of phytochemicals with antimicrobial agents: Potential strategy to counteract drug resistance. Chem Biol Interact 2019;298:294–303.

35 Miklasztos-Majdanic M, Kepa M, Wojtczycka RD, Idzik D, Wąsik TJ. Phenolic compounds diminish antibiotic resistance of staphylococcus aureus clinical strains. Int J Environ Res Public Health 2018;15(10):2351.

36 Song M, Liu Y, Li T, Liu X, Hao Z, Ding S, et al. Plant natural Rava- noids against multidrug resistant pathogens. Adv Sci 2018;5(15):e1800749.

37 Bazzaz BSF, Khamehni B, Ostad MRZ, Hosseinzadeh H. In vitro evaluation of antibacterial activity of verbascoside, lemon verbena extract and caffeine in combination with gentamicin against multidrug resistant Staphylococcus aureus and Escherichia coli clinical isolates. Avicenna J Phytomed 2018;8(1):34–6.

38 Platthahnung PN, Chunts S, Vorathikunchai SP. Thai ethnomedi- cal plants as resistant modifying agents for combating Acinetobacter baumannii infections. BMC Complement Altern Med 2012;12(1):36.

39 Fadli M, Pagis JM, Mezroui NE, Abbad A, Hassani L. Artemisia herba-alba Asso and Cymbopogon citratus (DC.) Stapf essential oils and their capability to restore antibiotics efficacy. Ind Crops Prod 2016;89:199–204.

40 Gorlesko CL, Kiselev HV. Budanova EV. Zamyatnin AA, Ikryannikova LN. Plant secondary metabolites in the battle of drugs and drug-resistant bacteria: new heroes or worse clones of antibiotics? Rev Microbiol 2016;47(3):1312–34.

41 Dragostin OM, Samal SK, Dash M, Lupsacu F, Panzarin A, Tuchiu C, et al. New antimicrobial chitosan derivatives for wound dress- ing applications. Carbohydr Polym 2017;143:46–52.

42 Fadli M, Pagis JM, Mezroui NE, Abbad A, Hassani L. Artemisia herba-alba Asso and Cymbopogon citratus (DC.) Stapf essential oils and their capability to restore antibiotics efficacy. Ind Crops Prod 2016;89:199–204.

43 Khameneh B, Iranshahy M, Soheili V, Fazly Bazzaz BS. Review on medicinal plants: Three-dimensional printed alginate/TEPOM-oxidized cellulose nanofibril scaffolds for bone tissue engineering. Biomacromolecules 2018;19(11):4442–52.

44 Farooqui A, Khan A, Borghetto I, Kazmi SU, Rubino S, Paglietti B. Synergistic antimicrobial activity of camellia sinensis and juglans regia against multidrug-resistant bacteria. PLoS One 2015;10(2):39451.

45 Fadli M, Pagis JM, Mezroui NE, Abbad A, Hassani L. Artemisia herba-alba Asso and Cymbopogon citratus (DC.) Stapf essential oils and their capability to restore antibiotics efficacy. Ind Crops Prod 2016;89:199–204.

46 Song M, Liu Y, Li T, Liu X, Hao Z, Ding S, et al. Plant natural Rava- Noids against multidrug resistant pathogens. Adv Sci 2018;5(15):e1800749.

47 Bazzaz BSF, Khamehni B, Ostad MRZ, Hosseinzadeh H. In vitro evaluation of antibacterial activity of verbascoside, lemon verbena extract and caffeine in combination with gentamicin against multidrug resistant Staphylococcus aureus and Escherichia coli clinical isolates. Avicenna J Phytomed 2018;8(1):34–6.

48 Platthahnung PN, Chunts S, Vorathikunchai SP. Thai ethnomeda- cal plants as resistant modifying agents for combating Acinetobacter baumannii infections. BMC Complement Altern Med 2012;12(1):36.
52 Ghaneian MT, Ehrampoush MH, Jafari A, Hekmatamirghaddam S, Mahmoudi M. Antimicrobial activity, toxicity and stability of phyto as a novel surface disinfectant. Environ Health Eng Manag J 2017;2 (1):3–6.
53 Sengun IY, Senturk S, Gul S, Kilic G. Potential of essential oil combinations and air disinfection. Lett Appl Microbiol 2021;72(3):26–34.
54 Vidacs A, Kerekes E, Rajko R, Petkovits T, Aliharbi NS, Khaled JM, et al. Optimization of essential oil-based natural disinfectants against Listeria monocytogenes and Escherichia coli biofilms formed on polypropylene surfaces. J Mol Liq 2018;255:62–72.
55 Guil-Guerrero JL, Ramos L, Moreno C, Zuniga-Paredes JC, Carlosama-Yepez M, Ruales P. Antimicrobial activity of plant-food by-products: a review focusing on the tropics. Livest Sci 2016;189:32–40.
56 Lee JI, Cui X, Chai KF, Zhao G, Chen WN. Interfacial assembly of a cashew nut (Anacardium occidentale) testa extract onto a cellu-lose-based film from sugarcane bagasse to produce an active packag-ing film with pH-triggered release mechanism. Food Bioprocess Technol 2020;13(1):501–10.
57 Trigo JP, Alexandre EMC, Sariava JA, Pintado ME. High value-added compounds from fruit and vegetable by-products—characteri-zation, bioactivities, and application in the development of novel food products. Crit Rev Food Sci Nutr 2020;60(8):1388–416.
58 Song M, Liu Y, Li T, Liu X, Hao Z, Ding S, et al. Plant natural flavo-noids against multidrug resistant pathogens. Adv Sci 2021;8(200):1900264.
59 Phuthalang PN, Chissn S, Voravuthikunchai SP. Thai ethnopharmaco-dicinal plants as resistant modifying agents for combating Acine-to bacter baumannii infections. BMC Complement Altern Med 2012:12(1):1–5.
60 Paddon CJ, Westfall PJ, Pitera DJ, Benjamin K, Fisher K, McPhee D, et al. High-level semi-synthetic production of the potent antimalarial artemisinin. Nature 2013;496(7446):528.
61 Ng KR, Lye X, Mark R, Chen WN. Antimicrobial and antioxidant activities of phenolic metabolites from flavonoid-producing yeast: Potential as natural food preservatives. Food Chem 2019;270:123–9.
62 Watching peptide drugs grow up. Chem Eng News Arch 2005;83 (11):77–24.
63 Hippsley-Cox J, Young D, Coupland C, Shannon KM, San Tan P, Harrison DA, et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart 2020;106(19):1503–11.
64 Chai KF, Voo AYH, Chen WN. Bioactive peptides from food fer-mentation: a comprehensive review of their sources, bioactivities, applications, and future development. Compr Rev Food Sci Food Saf 2020;19(6):3825–35.
65 Hussin FS, Chay SY, Hussin ASM, IJaddullah WZW, Muhaidin BJ, Abd Ghanii MS, et al. GABA enhancement by simple carbohydrates in yoghurt fermented using novel, self-cloned Lactobacillus planta-rum Taj-Apis562 and metabolomics profiling. Sci Rep 2021;11(1):1–12.
66 Chen Y, Li C, Xue J, Kwok LY, Yang J, Zhang H, et al. Characterization of angiotensin-converting enzyme inhibitory activity of fer-mented milk produced by Lactobacillus helveticus. J Dairy Sci 2015;98(8):3151–4.
67 Sah BNP, Vasiljevic T, McKechnie S, Donkor O. Antioxidant pep-tides isolated from synbiotic yoghurt exhibit antiproliferative activi-ties against HT-29 colon cancer cells. Int Dairy J 2016;63(3):1–6.
68 Spiller R. Probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol Ther 2008;28(3):38–96.
69 Teng TS, Chiu YL, Chai KF, Chen WN. Fermentation for future food systems: Precision fermentation can complement the scope and applications of traditional fermentation. EMBO Rep 2021;22(5): e52680.
70 Tonolo F, Fiorese F, Moretto L, Folda A, Scalco V, Grinzato A, et al. Identification of new peptides from fermented milk showing anti-oxidant properties: mechanism of action. Ani-oxidants 2020;9(4):117.
71 Baptista DP, Galli BD, Cavalheiro FG, Negrao F, Eberlin MN, Gigante ML. Lactobacillus helveticus LH-Boa favours the release of bioactive peptide during Prato cheese ripening. Int Dairy J 2018;87:77–84.
72 Yu D, Feng MQ, Sun J, Xu XL, Zhou GH. Protein degradation and peptide formation with antioxidant activity in pork protein extracts inoculated with Lactobacillus plantarum and Staphylococcus simulans. Meat Sci 2020;170:107938.
73 Chen Y, Gao X, Wei Y, Liu Q, Jiang Y, Zhao L, et al. Isolation, purifi-cation and the anti-hypertensive effect of a novel angiotensin I-con-verting enzyme (ACE) inhibitory peptide from Ruditapes philippinarum fermented with Bacillus natto. Food Funct 2019;10(1):520–7.
74 Taniguchi M, Aida R, Saito K, Ochiai A, Takesono S, Saitoh E, et al. Identification and characterization of multifunctional cationic pep-tides from traditional Japanese fermented soybean Natto extracts. J Biosci Bioeng 2010;109(4):472–8.
75 Fontoura R, Daroit DJ, Correa APF, Moreeso KS, Santi L, Bays-da-Silva WO, et al. Characterization of a novel antioxidant peptide from feather keratin hydrolysates. New Biotechnol 2019;49:71–6.